skip to content
Ensuring access to medicines : how to stimulate innovation to meet patients' needs? Preview this item
ClosePreview this item
Checking...

Ensuring access to medicines : how to stimulate innovation to meet patients' needs?

Author: Dimitra PanteliSuzanne Edwards, (Independent researcher)Erica RichardsonW PalmEuropean Observatory on Health Systems and Policies,All authors
Publisher: Copenhagen, Denmark : World Health Organization, Regional Office for Europe, [2018]
Series: Policy brief (World Health Organization. Regional Office for Europe), no. 29.
Edition/Format:   eBook : Document : International government publication : EnglishView all editions and formats
Summary:
1. The development of innovative medicines is essential for making progress in preventing and treating diseases. However, the high price tags put on new medicines do not always reflect the value added for patients. Also, persisting unmet clinical need in the population suggests a misalignment of pharmaceutical research and development efforts.2. There is a growing consensus that existing policies need to be  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Material Type: Document, Government publication, International government publication, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Dimitra Panteli; Suzanne Edwards, (Independent researcher); Erica Richardson; W Palm; European Observatory on Health Systems and Policies,; World Health Organization. Regional Office for Europe,
OCLC Number: 1081377440
Notes: At head of title: Addressing policy failures in pharmaceuticals.
Description: 1 online resource (1 PDF file (29 pages)) : illustrations.
Series Title: Policy brief (World Health Organization. Regional Office for Europe), no. 29.
Responsibility: authors, Dimitra Panteli, Suzanne Edwards ; editors, Erica Richardson, Willy Palm.

Abstract:

1. The development of innovative medicines is essential for making progress in preventing and treating diseases. However, the high price tags put on new medicines do not always reflect the value added for patients. Also, persisting unmet clinical need in the population suggests a misalignment of pharmaceutical research and development efforts.2. There is a growing consensus that existing policies need to be rethought and new approaches need to be found to strike the delicate balance between stimulating true innovation, particularly towards addressing unmet needs, and ensuring both financial sustainability for health systems and accessibility for patients.3. While small and medium-sized enterprises (SMEs), academia and public institutions play a major role in driving innovation and enriching the industry's pipeline, the commercialization of new products is almost exclusively in the hands of large companies, often as a result of mergers and acquisitions. This is a concern for the sustainability of pharmaceutical research and development (R&D) infrastructure.4. The impact of public funding on pharmaceutical innovation cannot be underestimated. A stronger implementation of public interest provisions along the life cycle of pharmaceuticals, including "fair return of investment", is required.5. For public finance of R&D to facilitate better alignment of innovation with unmet clinical needs, more discrimination could be introduced in the reward system. Through limiting the risks, reducing R&D costs and/or increasing the innovation potential, incentives can be created for industry to re-embrace revolutionary - or even disruptive - innovation.6. More can also be done to improve coordination and priority-setting across R&D efforts, ideally globally, but with further refinement from an EU level to reflect regional priorities. In this respect, the creation of an entity to monitor clinical need, in conjunction with inequalities in access to essential medicines, merits consideration.7. Improving the efficiency of evidence generation in clinical research is not only good for driving down the costs of clinical trials, it can also help to remediate some of the related technical and ethical challenges, such as the fragmentation and duplication that unnecessarily expose patients to risk; the lack of comparative effectiveness data; the evidence gaps regarding specific patient groups and therapeutic areas; or the perceived conflicts of interest and related publication bias.8. Raising the bar for market entry by requiring that a new product demonstrate its superiority or equivalence to existing alternatives could encourage manufacturers to focus more on areas with limited treatment options and facilitate increased alignment with specifications applied in post-marketing evaluations for pricing and/or reimbursement (for example, Health Technology Assessment). Increased collaboration and alignment on evidentiary requirements between and within EU Member States are likely to simplify evidence generation for manufacturers as well as increase efficiency on the evaluators' side.9. Only a comprehensive approach that combines initiatives to guarantee funding, optimize evidence generation and align regulatory requirements can effectively tackle innovation deficits. An overall vision with greater policy coherence and backed by strong political commitment and transparency is needed.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1081377440> # Ensuring access to medicines : how to stimulate innovation to meet patients' needs?
    a schema:Book, schema:CreativeWork, schema:MediaObject ;
    library:oclcnum "1081377440" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/dk> ;
    rdfs:comment "Unknown 'gen' value: igp" ;
    schema:about <http://experiment.worldcat.org/entity/work/data/8856964671#Topic/drug_discovery> ; # Drug Discovery
    schema:about <http://experiment.worldcat.org/entity/work/data/8856964671#Topic/technology_pharmaceutical> ; # Technology, Pharmaceutical
    schema:about <http://experiment.worldcat.org/entity/work/data/8856964671#Topic/drug_industry> ; # Drug Industry
    schema:about <http://experiment.worldcat.org/entity/work/data/8856964671#Topic/pharmaceutical_research> ; # Pharmaceutical Research
    schema:about <http://experiment.worldcat.org/entity/work/data/8856964671#Topic/health_policy> ; # Health Policy
    schema:about <http://experiment.worldcat.org/entity/work/data/8856964671#Topic/health_services_accessibility> ; # Health Services Accessibility
    schema:author <http://experiment.worldcat.org/entity/work/data/8856964671#Person/edwards_suzanne_independent_researcher> ; # (Independent researcher) Suzanne Edwards
    schema:author <http://experiment.worldcat.org/entity/work/data/8856964671#Person/panteli_dimitra> ; # Dimitra Panteli
    schema:bookFormat schema:EBook ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/8856964671#Organization/european_observatory_on_health_systems_and_policies> ; # European Observatory on Health Systems and Policies,
    schema:contributor <http://experiment.worldcat.org/entity/work/data/8856964671#Organization/world_health_organization_regional_office_for_europe> ; # World Health Organization. Regional Office for Europe,
    schema:datePublished "2018" ;
    schema:description "1. The development of innovative medicines is essential for making progress in preventing and treating diseases. However, the high price tags put on new medicines do not always reflect the value added for patients. Also, persisting unmet clinical need in the population suggests a misalignment of pharmaceutical research and development efforts.2. There is a growing consensus that existing policies need to be rethought and new approaches need to be found to strike the delicate balance between stimulating true innovation, particularly towards addressing unmet needs, and ensuring both financial sustainability for health systems and accessibility for patients.3. While small and medium-sized enterprises (SMEs), academia and public institutions play a major role in driving innovation and enriching the industry's pipeline, the commercialization of new products is almost exclusively in the hands of large companies, often as a result of mergers and acquisitions. This is a concern for the sustainability of pharmaceutical research and development (R&D) infrastructure.4. The impact of public funding on pharmaceutical innovation cannot be underestimated. A stronger implementation of public interest provisions along the life cycle of pharmaceuticals, including "fair return of investment", is required.5. For public finance of R&D to facilitate better alignment of innovation with unmet clinical needs, more discrimination could be introduced in the reward system. Through limiting the risks, reducing R&D costs and/or increasing the innovation potential, incentives can be created for industry to re-embrace revolutionary - or even disruptive - innovation.6. More can also be done to improve coordination and priority-setting across R&D efforts, ideally globally, but with further refinement from an EU level to reflect regional priorities. In this respect, the creation of an entity to monitor clinical need, in conjunction with inequalities in access to essential medicines, merits consideration.7. Improving the efficiency of evidence generation in clinical research is not only good for driving down the costs of clinical trials, it can also help to remediate some of the related technical and ethical challenges, such as the fragmentation and duplication that unnecessarily expose patients to risk; the lack of comparative effectiveness data; the evidence gaps regarding specific patient groups and therapeutic areas; or the perceived conflicts of interest and related publication bias.8. Raising the bar for market entry by requiring that a new product demonstrate its superiority or equivalence to existing alternatives could encourage manufacturers to focus more on areas with limited treatment options and facilitate increased alignment with specifications applied in post-marketing evaluations for pricing and/or reimbursement (for example, Health Technology Assessment). Increased collaboration and alignment on evidentiary requirements between and within EU Member States are likely to simplify evidence generation for manufacturers as well as increase efficiency on the evaluators' side.9. Only a comprehensive approach that combines initiatives to guarantee funding, optimize evidence generation and align regulatory requirements can effectively tackle innovation deficits. An overall vision with greater policy coherence and backed by strong political commitment and transparency is needed."@en ;
    schema:editor <http://experiment.worldcat.org/entity/work/data/8856964671#Person/palm_w> ; # W. Palm
    schema:editor <http://experiment.worldcat.org/entity/work/data/8856964671#Person/richardson_erica> ; # Erica Richardson
    schema:exampleOfWork <http://worldcat.org/entity/work/id/8856964671> ;
    schema:genre "Government publication"@en ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://worldcat.org/issn/1997-8073> ; # Policy brief (World Health Organization. Regional Office for Europe) ;
    schema:name "Ensuring access to medicines : how to stimulate innovation to meet patients' needs?"@en ;
    schema:productID "1081377440" ;
    schema:url <https://www.ncbi.nlm.nih.gov/books/NBK526400/> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1081377440> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/8856964671#Organization/european_observatory_on_health_systems_and_policies> # European Observatory on Health Systems and Policies,
    a schema:Organization ;
    schema:name "European Observatory on Health Systems and Policies," ;
    .

<http://experiment.worldcat.org/entity/work/data/8856964671#Organization/world_health_organization_regional_office_for_europe> # World Health Organization. Regional Office for Europe,
    a schema:Organization ;
    schema:name "World Health Organization. Regional Office for Europe," ;
    .

<http://experiment.worldcat.org/entity/work/data/8856964671#Person/edwards_suzanne_independent_researcher> # (Independent researcher) Suzanne Edwards
    a schema:Person ;
    schema:familyName "Edwards" ;
    schema:givenName "Suzanne" ;
    schema:name "(Independent researcher) Suzanne Edwards" ;
    .

<http://experiment.worldcat.org/entity/work/data/8856964671#Person/panteli_dimitra> # Dimitra Panteli
    a schema:Person ;
    schema:familyName "Panteli" ;
    schema:givenName "Dimitra" ;
    schema:name "Dimitra Panteli" ;
    .

<http://experiment.worldcat.org/entity/work/data/8856964671#Person/richardson_erica> # Erica Richardson
    a schema:Person ;
    schema:familyName "Richardson" ;
    schema:givenName "Erica" ;
    schema:name "Erica Richardson" ;
    .

<http://experiment.worldcat.org/entity/work/data/8856964671#Topic/health_services_accessibility> # Health Services Accessibility
    a schema:Intangible ;
    schema:name "Health Services Accessibility"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8856964671#Topic/pharmaceutical_research> # Pharmaceutical Research
    a schema:Intangible ;
    schema:name "Pharmaceutical Research"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8856964671#Topic/technology_pharmaceutical> # Technology, Pharmaceutical
    a schema:Intangible ;
    schema:name "Technology, Pharmaceutical"@en ;
    .

<http://worldcat.org/issn/1997-8073> # Policy brief (World Health Organization. Regional Office for Europe) ;
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1081377440> ; # Ensuring access to medicines : how to stimulate innovation to meet patients' needs?
    schema:issn "1997-8073" ;
    schema:name "Policy brief (World Health Organization. Regional Office for Europe) ;" ;
    schema:name "Policy brief," ;
    .

<http://www.worldcat.org/title/-/oclc/1081377440>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/1081377440> ; # Ensuring access to medicines : how to stimulate innovation to meet patients' needs?
    schema:dateModified "2020-01-17" ;
    void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.